Dermata Therapeutics, Inc. DRMA

Company Overview

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing dermatology therapies for medical and aesthetic skin conditions. The company operates within the biopharmaceutical and dermatology sectors, with a primary emphasis on inflammatory skin diseases, acne treatment, and aesthetic dermatology. Its lead product candidates are based on a proprietary platform utilizing naturally derived components intended to treat skin conditions through topical application. The company’s core revenue model currently centers on research and development activities and capital raising, as it has not yet commercialized approved products based on publicly available filings.

Dermata’s primary development programs include XYNGARI, a topical product candidate derived from a naturally sourced bacterium intended for the treatment of acne, rosacea, and hyperhidrosis, and DMT410, a combination platform designed to enhance topical drug delivery for aesthetic and medical dermatology applications. The company primarily targets dermatology patients, dermatologists, and the broader aesthetic medicine market. Dermata was founded in 2014 and became publicly traded through a merger transaction involving a special purpose acquisition company in 2022. Its strategic positioning is tied to its differentiated biologic-derived technology platform and focus on non-invasive dermatologic therapies.